Mizoribine in steroid-dependent nephrotic syndrome of childhood
Mizoribine in steroid-dependent nephrotic syndrome of childhood
复制标题
DOI：
10.1007/s004670050351
复制
发表时间：
1997-10-01
影响因子：
3
通讯作者：
Sakano, T
中科院分区：
文献类型：
--
作者：
Hamasaki, T;Mori, M;Sakano, T
我们评估了一个新开发的免疫抑制剂，咪唑立宾（剂量为3毫克/公斤体重每天），在9名儿童激素依赖性肾病综合征1年的过程。两名患者可以停止类固醇治疗，第三名患者的类固醇维持剂量可以减少到咪唑立宾治疗前的一半以下。其余6例患者无获益。在治疗过程中未观察到咪唑立宾的不良反应。
We evaluated a 1-year course of a newly developed immunosuppressant, mizoribine (at a dosage of 3 mg/kg body weight per day), in nine children with steroid-dependent nephrotic syndrome. Steroid treatment could be discontinued in two patients and the maintenance dosage of steroid could be reduced to less than half of that given before mizoribine therapy in a third. There were no beneficial effects in the remaining six patients. No adverse effects of mizoribine were observed during the course of therapy.